Last reviewed · How we verify
Approved ICIs
At a glance
| Generic name | Approved ICIs |
|---|---|
| Sponsor | MiNK Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
- Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (NA)
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors (PHASE1)
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Approved ICIs CI brief — competitive landscape report
- Approved ICIs updates RSS · CI watch RSS
- MiNK Therapeutics portfolio CI